Skip to main content

UBS Reaffirms Their Hold Rating on Solventum Corporation (SOLV)

Tipranks - Tipranks - Tue Mar 3, 8:20AM CST

In a report released today, Kevin Caliendo from UBS maintained a Hold rating on Solventum Corporation, with a price target of $82.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Caliendo is a 4-star analyst with an average return of 5.4% and a 58.90% success rate. Caliendo covers the Healthcare sector, focusing on stocks such as Align Tech, DENTSPLY SIRONA, and Medline.

In addition to UBS, Solventum Corporation also received a Hold from TipRanks – OpenAI’s OpenAI Medical – Care Facilities in a report issued on February 27. However, on the same day, KeyBanc maintained a Buy rating on Solventum Corporation (NYSE: SOLV).

See the top stocks recommended by analysts >>

Based on Solventum Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2 billion and a net profit of $63 million. In comparison, last year the company earned a revenue of $2.08 billion and had a net profit of $31 million

Read More on SOLV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).